Tislelizumab Triplet Shows Numerical Progression-Free Survival Prolongation in Colorectal Cancer
A randomized phase II trial found that adding tislelizumab to cetuximab and irinotecan numerically prolonged progression-free survival in heavily pre-treated ...

